纳武单抗诱导肺腺癌急性严重毒性

The Open cancer immunology journal Pub Date : 2018-03-26 DOI:10.2174/1876401001807010001

J. A. Sagarduy, E. A. Uribelarrea, I. Echevarria, Sergio Carrera Revilla, A. M. Llarena, G. L. Vivanco

{"title":"纳武单抗诱导肺腺癌急性严重毒性","authors":"J. A. Sagarduy, E. A. Uribelarrea, I. Echevarria, Sergio Carrera Revilla, A. M. Llarena, G. L. Vivanco","doi":"10.2174/1876401001807010001","DOIUrl":null,"url":null,"abstract":"Immunotherapy has recently revolutionized the world of oncology. Nivolumab an IgG4 targeting PD-1 receptor has been approved in metastatic melanoma, renal cell carcinoma, Hodgkin lymphoma and non-small cell lung cancer. It works as a checkpoint inhibitor, allowing the immune system to clear cancer, and it is this mechanism of action which explains its toxicity also named as immmunerelated adverse events.","PeriodicalId":93682,"journal":{"name":"The Open cancer immunology journal","volume":"7 1","pages":"1-6"},"PeriodicalIF":0.0000,"publicationDate":"2018-03-26","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"Nivolumab Induced Acute Severe Toxicity in Lung Adenocarcinoma\",\"authors\":\"J. A. Sagarduy, E. A. Uribelarrea, I. Echevarria, Sergio Carrera Revilla, A. M. Llarena, G. L. Vivanco\",\"doi\":\"10.2174/1876401001807010001\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"Immunotherapy has recently revolutionized the world of oncology. Nivolumab an IgG4 targeting PD-1 receptor has been approved in metastatic melanoma, renal cell carcinoma, Hodgkin lymphoma and non-small cell lung cancer. It works as a checkpoint inhibitor, allowing the immune system to clear cancer, and it is this mechanism of action which explains its toxicity also named as immmunerelated adverse events.\",\"PeriodicalId\":93682,\"journal\":{\"name\":\"The Open cancer immunology journal\",\"volume\":\"7 1\",\"pages\":\"1-6\"},\"PeriodicalIF\":0.0000,\"publicationDate\":\"2018-03-26\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"The Open cancer immunology journal\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://doi.org/10.2174/1876401001807010001\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"\",\"JCRName\":\"\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"The Open cancer immunology journal","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.2174/1876401001807010001","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}

引用次数: 0

摘要

免疫疗法最近彻底改变了肿瘤学的世界。Nivolumab是一种靶向PD-1受体的IgG4，已被批准用于转移性黑色素瘤、肾细胞癌、霍奇金淋巴瘤和非小细胞肺癌癌症。它作为一种检查点抑制剂，使免疫系统清除癌症，正是这种作用机制解释了它的毒性也被称为免疫相关不良事件。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

查看原文本刊更多论文

Nivolumab Induced Acute Severe Toxicity in Lung Adenocarcinoma

Immunotherapy has recently revolutionized the world of oncology. Nivolumab an IgG4 targeting PD-1 receptor has been approved in metastatic melanoma, renal cell carcinoma, Hodgkin lymphoma and non-small cell lung cancer. It works as a checkpoint inhibitor, allowing the immune system to clear cancer, and it is this mechanism of action which explains its toxicity also named as immmunerelated adverse events.

求助全文

通过发布文献求助，成功后即可免费获取论文全文。去求助

来源期刊

The Open cancer immunology journal

自引率

0.00%

发文量